Swiss National Bank Purchases 36,160 Shares of Cencora, Inc. $COR

Swiss National Bank raised its position in shares of Cencora, Inc. (NYSE:COR) by 7.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 540,860 shares of the company’s stock after purchasing an additional 36,160 shares during the period. Swiss National Bank’s holdings in Cencora were worth $169,906,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kemnay Advisory Services Inc. acquired a new stake in shares of Cencora in the 4th quarter valued at $25,000. Oakworth Capital Inc. acquired a new position in shares of Cencora during the 4th quarter worth $26,000. Elyxium Wealth LLC acquired a new position in shares of Cencora during the 4th quarter worth $27,000. Archer Investment Corp raised its holdings in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC bought a new stake in shares of Cencora during the 4th quarter worth $29,000. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cencora

In other news, Director Lauren M. Tyler acquired 550 shares of the stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of $270.23 per share, with a total value of $148,626.50. Following the completion of the purchase, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This represents a 14.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.38% of the company’s stock.

Cencora Trading Down 0.1%

NYSE COR opened at $307.72 on Monday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The company has a market cap of $59.87 billion, a price-to-earnings ratio of 23.60, a price-to-earnings-growth ratio of 1.71 and a beta of 0.58. The business’s fifty day moving average is $279.98 and its 200 day moving average is $317.52.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same period in the previous year, the company earned $4.42 EPS. Cencora’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora announced that its board has approved a stock repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 3.9% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is 18.40%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on COR shares. Wells Fargo & Company reduced their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Morgan Stanley set a $342.00 target price on Cencora in a research note on Friday, May 8th. Citigroup dropped their target price on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Evercore set a $360.00 price target on shares of Cencora in a research note on Wednesday, April 8th. Finally, Barclays decreased their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $367.75.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.